Compositions and methods for tunable regulation of il15 and light

By using nucleic acid molecules and ligands to dynamically regulate polypeptide payloads and LIGHT in cells, the method addresses the challenge of suboptimal activation, achieving enhanced therapeutic efficacy in cancer treatment through controlled activity levels and improved cytotoxicity.

AU2024415858A1Pending Publication Date: 2026-07-16OBSIDIAN THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
OBSIDIAN THERAPEUTICS INC
Filing Date
2024-12-26
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

Existing methods struggle to efficiently regulate the biological activity levels of polypeptide payloads and LIGHT in cells, particularly in tumor infiltrating lymphocytes, leading to suboptimal activation and functionality.

Method used

The use of nucleic acid molecules and ligands to modulate the activity of polypeptide payloads and LIGHT by administering specific doses of ligands that interact with designated DRDs, allowing for dynamic regulation of their activity levels, including the introduction of these molecules into cells through methods like electroporation or nanowires, and the use of genetically engineered cells such as T cells and NK cells to express these molecules.

Benefits of technology

This approach enables precise control over the activity levels of polypeptide payloads and LIGHT, enhancing their functional activation and expansion, thereby improving their therapeutic efficacy, particularly in cancer treatment by promoting cytotoxicity against tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000050_0000
    Figure 00000050_0000
  • Figure 00000050_0001
    Figure 00000050_0001
  • Figure 00000051_0000
    Figure 00000051_0000
Patent Text Reader

Abstract

Provided herein are nucleic acid molecules comprising a first nucleic acid encoding a polypeptide payload operably linked to a first drug responsive domain (DRD) and a second nucleic acid encoding a LIGHT polypeptide operably linked to a second DRD. The abundance, availability, and / or biological activity of the polypeptide payload and the LIGHT polypeptide is regulated by interaction of an effective amount of the first and second nucleic acid with an effective amount of at least one ligand. Vectors and cells comprising the nucleic molecules provided herein are provided, as are methods of making and using the nucleic molecules.
Need to check novelty before this filing date? Find Prior Art